HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Serotonin 5-HT2 Receptor Antagonists

Drugs that bind to but do not activate SEROTONIN 5-HT2 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT2 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more specific 5-HT2 receptor subtypes.
Also Known As:
5-HT2 Antagonist; 5-HT2A Antagonist; 5-HT2B Antagonist; 5-HT2C Antagonist; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2B Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; 5 HT2 Antagonist; 5 HT2A Antagonist; 5 HT2B Antagonist; 5 HT2C Antagonist; Antagonist, 5-HT2; Antagonist, 5-HT2A; Antagonist, 5-HT2B; Antagonist, 5-HT2C; Serotonin 5 HT2 Receptor Antagonists; Serotonin 5 HT2A Receptor Antagonists; Serotonin 5 HT2B Receptor Antagonists; Serotonin 5 HT2C Receptor Antagonists
Networked: 105 relevant articles (13 outcomes, 23 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Poyurovsky, Michael: 3 articles (06/2020 - 03/2003)
2. Weizman, Abraham: 3 articles (06/2020 - 03/2003)
3. Gourdon, Jim C: 2 articles (08/2022 - 01/2018)
4. Huot, Philippe: 2 articles (08/2022 - 01/2018)
5. Nuara, Stephen G: 2 articles (08/2022 - 01/2018)
6. Simon, James A: 2 articles (01/2019 - 11/2017)
7. Kissling, Robert: 2 articles (01/2018 - 11/2017)
8. Yuan, James: 2 articles (01/2018 - 11/2017)
9. Cutler, Andrew J: 2 articles (04/2008 - 04/2008)
10. Weiden, Peter J: 2 articles (04/2008 - 04/2008)

Related Diseases

1. Psychotic Disorders (Schizoaffective Disorder)
2. Schizophrenia (Dementia Praecox)
3. Body Weight (Weight, Body)
4. Dyskinesias (Dyskinesia)
01/01/2018 - "The highly selective 5-HT2A antagonist EMD-281,014 reduces dyskinesia and psychosis in the l-DOPA-treated parkinsonian marmoset."
05/01/2006 - "Since l-DOPA induced dyskinesia (LID) may be mediated by over-sensitive D1-mediated signaling, the present study examined the effects of the selective 5-HT2A antagonist M100907 on LID behaviors in DA-depleted rats. "
01/01/1989 - "Although ritanserin is a potent 5-HT2 antagonist with very weak dopamine antagonist properties, this drug did not antagonize dyskinesias but induced them when administered at a high dose (30 mg/kg). "
08/01/2022 - "After induction of parkinsonism with MPTP, marmosets entered 3 streams of experiments, in which the following treatments were administered, in combination with l-3,4-dihydroxyphenylalanine (L-DOPA), after which dyskinesia, psychosis-like behaviours (PLBs) and parkinsonism were rated: 1. vehicle/vehicle, LY354740 (mGlu2/3 orthosteric agonist)/vehicle, LY354740/LY341495 1 mg/kg and LY354740/LY341495 3 mg/kg; 2. vehicle/vehicle, LY487379 (mGlu2 positive allosteric modulator)/vehicle, LY487379/LY341495 1 mg/kg and LY487379/LY341495 3 mg/kg; 3. vehicle/vehicle, EMD-281,014 (5-HT2A antagonist)/vehicle, EMD-281,014/LY341495 1 mg/kg and EMD-281,014/LY341495 3 mg/kg. Each of LY354740, LY487379 and EMD-281,014 reduced the severity of L-DOPA-induced dyskinesia, by 55%, 39% and 40%, respectively (all p < 0.001), as well as the severity of PLBs, by 48%, 36% and 41%, respectively (all p < 0.001). "
5. Parkinson Disease (Parkinson's Disease)

Related Drugs and Biologics

1. Ritanserin
2. Serotonin (5 Hydroxytryptamine)
3. Levodopa (L Dopa)
4. 5-HT2A Serotonin Receptor (5 HT2A Receptor)
5. Fluoxetine (Prozac)
6. Ketanserin
7. Antipsychotic Agents (Antipsychotics)
8. Mianserin
9. nefazodone (Serzone)
10. sarpogrelate

Related Therapies and Procedures

1. Oral Administration
2. Intravenous Administration
3. Induced Hyperthermia (Thermotherapy)
4. Aftercare (After-Treatment)